MOPP

MOPP is a combination chemotherapy regimen used to treat Hodgkin's disease. The acronym MOPP stands for the four drugs that make up the regimen: Mechlorethamine, Oncovin, Procarbazine, and Prednisone.

History

MOPP was the first combination chemotherapy regimen developed to treat Hodgkin's disease in the 1960s. It was developed by a team of researchers at the National Cancer Institute led by Vincent T. DeVita Jr. and George Canellos. MOPP was the first chemotherapy regimen that was able to cure advanced cancer.

Treatment

MOPP is administered in cycles, with each cycle lasting 28 days. Patients receive the four drugs on the first and eighth day of each cycle, and then have a rest period for the remaining days. The number of cycles a patient receives depends on the stage of their disease and their response to treatment.

Side Effects

Like all chemotherapy regimens, MOPP has potential side effects. These can include nausea, vomiting, hair loss, and fatigue. More serious side effects can include infertility, lung damage, and an increased risk of secondary cancers.

Alternatives

While MOPP was once the standard treatment for Hodgkin's disease, it has largely been replaced by other regimens such as ABVD and BEACOPP. These newer regimens are generally considered to be more effective and have fewer side effects.

See Also

• Chemotherapy
• Hodgkin's disease
• ABVD
• BEACOPP